Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19 - Seite 3

Media and Investor Relations

Contact: Brian Cooley

Email: [e-mail]

Sorrento and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB, DAR-T, Seprehvec, SOFUSA, COVISHIELD, COVIDROPS, COVI-MSC, COVIMARK, Fujovee and Ovydso are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA (SP-102) is a trademark of Semnur Pharmaceuticals, Inc. A proprietary name review by the FDA is planned.

ZTlido is a registered trademark owned by Scilex Pharmaceuticals Inc.

All other trademarks are the property of their respective owners.

2023 Sorrento Therapeutics, Inc. All Rights Reserved.